Compare · CHE vs REUN
CHE vs REUN
Side-by-side comparison of Chemed Corp (CHE) and Reunion Neuroscience Inc. (REUN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CHE and REUN operate in Medical/Nursing Services (Health Care), so they compete in similar markets.
- CHE carries a market cap of $5.83B.
- CHE has hit the wire 11 times in the past 4 weeks while REUN has been quiet.
- CHE has more recent analyst coverage (6 ratings vs 0 for REUN).
- Company
- Chemed Corp
- Reunion Neuroscience Inc.
- Price
- $439.56-0.52%
- $1.13+1.80%
- Market cap
- $5.83B
- -
- 1M return
- +3.22%
- -
- 1Y return
- -19.96%
- -
- Industry
- Medical/Nursing Services
- Medical/Nursing Services
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 11
- 0
- Recent ratings
- 6
- 0
Chemed Corp
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates in two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned branches and independent contractors, and franchised locations. Chemed Corporation was incorporated in 1970 and is headquartered in Cincinnati, Ohio.
Latest CHE
- Roto-Rooter Buys Franchise Territory in Corpus Christi, Rio Grande Valley, and Beaumont, Texas
- Director Walsh George J Iii sold $218,915 worth of Capital Stock (500 units at $437.83), decreasing direct ownership by 13% to 3,209 units (SEC Form 4)
- Chemed Corp filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Walsh George J Iii was granted 386 units of Capital Stock, increasing direct ownership by 12% to 3,709 units (SEC Form 4)
- Director Mount John Meredith Jr. was granted 386 units of Capital Stock, increasing direct ownership by 42% to 1,316 units (SEC Form 4)
- Director Mccarthy Eileen P was granted 386 units of Capital Stock, increasing direct ownership by 45% to 1,241 units (SEC Form 4)
- Director Lindell Andrea R was granted 386 units of Capital Stock, increasing direct ownership by 7% to 5,925 units (SEC Form 4)
- Director Heaney Christopher J was granted 386 units of Capital Stock, increasing direct ownership by 16% to 2,775 units (SEC Form 4)
- Director Grace Patrick P was granted 386 units of Capital Stock, increasing direct ownership by 12% to 3,723 units (SEC Form 4)
- Director Delyons Ron was granted 386 units of Capital Stock, increasing direct ownership by 23% to 2,052 units (SEC Form 4)
Latest REUN
- SEC Form 15-12G filed by Reunion Neuroscience Inc.
- Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
- Reunion Neuroscience Completes Take-Private Setup: Delisting & Consideration Details
- SEC Form 6-K filed by Reunion Neuroscience Inc.
- SEC Form SC 13D/A filed by Reunion Neuroscience Inc. (Amendment)
- SEC Form F-10POS filed by Reunion Neuroscience Inc.
- SEC Form S-8 POS filed by Reunion Neuroscience Inc.
- SEC Form S-8 POS filed by Reunion Neuroscience Inc.
- SEC Form 25-NSE filed by Reunion Neuroscience Inc.
- Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement